| (Values in U.S. Thousands) | Nov, 2022 | Nov, 2021 | Nov, 2020 | Nov, 2019 | Nov, 2018 |
| Sales | 70 | 0 | 1,400 | 3,480 | 1,710 |
| Sales Growth | unch | -100.00% | -59.77% | +103.51% | -68.91% |
| Net Income | -2,890 | -5,150 | -3,390 | -8,080 | -13,750 |
| Net Income Growth | +43.88% | -51.92% | +58.04% | +41.24% | -55.19% |
Intellipharmaceutics International Inc (IPCIF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada.